

# The evolution and revolution of artificial intelligence in hepatology: From current applications to future paradigms

 Cem Simsek

Department of Gastroenterology, Hacettepe University School of Medicine, Ankara, Turkiye

## Current Landscape of AI in Hepatology

The integration of artificial intelligence (AI) into hepatology marks a transformative era in liver disease management and research. This paradigm shift extends beyond data interpretation, ushering in an age of decision augmentation in liver care. Machine learning algorithms, particularly deep neural networks, demonstrate unprecedented proficiency in analyzing complex hepatological data, navigating intricate interactions between genetic, environmental, and lifestyle factors. Here, I aim to highlight the significant advancements AI brings to liver disease management, offering insights into emerging technologies and their implications for improving patient outcomes.

The exponential growth of AI applications in hepatology is evident, with over 800 PubMed hits, half from the last two years. AI applications span the entire spectrum of liver care, from diagnostic imaging to prognostics. Deep learning algorithms have revolutionized hepatological imaging analysis, particularly in liver fibrosis quantification and tumor characterization. AI-driven techniques are at least comparable to traditional methods in liver fibrosis staging.<sup>[1]</sup> Studies demonstrate that deep learning-based automated segmentation and volumetric analysis of liver CT images outperform semi-automated methods, especially in living liver transplant donor assessment.<sup>[2]</sup> Machine learning algorithms applied to radiomics features extracted from CT and MRI images show a remarkable ability in predicting microvascular invasion, a critical prognostic factor in HCC.<sup>[3]</sup> Studies have demonstrated that CT-based radiomics, combined with clinical features, outperform conventional staging systems in predicting early HCC recurrence after curative resection.<sup>[4]</sup> In ultrasound imaging, AI assistance significantly improves the detection of focal liver lesions, particularly by non-expert operators,<sup>[5]</sup> suggesting potential utility in resource-limited settings.<sup>[6]</sup>

The evolution from traditional statistical methods to sophisticated machine learning models has enhanced the ability to predict disease progression and treatment outcomes in hepatology. In MAFLD, machine learning models integrating clinical and laboratory data demonstrate su-

perior performance in predicting significant fibrosis compared to traditional biomarkers.<sup>[7]</sup> These models can offer nuanced risk assessments, enabling earlier interventions and personalized management strategies. In liver transplantation, AI-driven dynamic risk assessment represents a paradigm shift in organ allocation and post-transplant care. Machine learning models show superior performance in predicting both short-term complications and long-term outcomes after liver transplantation.<sup>[8]</sup> These advancements hold the potential to optimize organ allocation, personalize post-transplant management, and improve overall transplant outcomes.

AI-enabled early warning systems represent a major advancement in predicting and preventing complications.<sup>[9]</sup> Novel machine learning models show promise in ruling out high-risk varices and avoiding unnecessary endoscopies in patients with compensated cirrhosis.<sup>[10]</sup> Similarly, machine learning models demonstrate high accuracy in predicting mortality in patients with hepatic encephalopathy, outperforming clinically used models.<sup>[11]</sup> These systems analyze subtle patterns in clinical and laboratory data that may elude human observation, providing hepatologists with valuable tools for proactive patient management. In HCC management, AI is guiding treatment strategies beyond initial diagnosis. AI-based decision-making tools improve adjuvant liver-directed treatment recommendations for unresectable HCC in patients who previously underwent transarterial chemoembolization. Such tools have the potential to optimize treatment sequencing and improve overall patient outcomes.<sup>[12,13]</sup>

The application of AI in hepatology extends beyond traditional clinical boundaries. In drug discovery, AI algorithms are accelerating the identification of novel therapeutic targets for liver diseases. Machine learning models analyze large-scale genomic and proteomic data, unveiling new insights into the molecular underpinnings of liver diseases and potentially identifying novel drug candidates.<sup>[14]</sup> Another novel concept of digital liver twins, powered by AI, represents an exciting frontier in personalized medicine. These computational models could simulate an individual patient's liver, allowing for virtual drug trials, personalized lifestyle interventions, and optimization of treatment strategies. While still in its infancy, this approach holds promise for revolutionizing individualized patient care in hepatology.<sup>[15]</sup>

**How to cite this article:** Simsek C. The evolution and revolution of artificial intelligence in hepatology: From current applications to future paradigms. *Hepatology Forum* 2024; 5(3):97–99.

**Received:** June 20, 2024; **Accepted:** June 30, 2024; **Available online:** July 02, 2024

**Corresponding author:** Cem Simsek; Hacettepe Universitesi Tip Fakultesi, Gastroenteroloji Anabilim Dalı, Ankara, Turkiye

**Phone:** +1 443 467 55 45; **e-mail:** cemgsimsek@gmail.com



OPEN ACCESS  
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

*Hepatology Forum* - Available online at [www.hepatologyforum.org](http://www.hepatologyforum.org)

## Emerging AI Frontiers in Hepatology

Emerging AI frontiers in hepatology include Large Language Models (LLM) and Natural Language Processing (NLP), which are revolutionizing the field by extracting invaluable insights from unstructured clinical data. Its applications span from automated analysis of electronic health records to accelerating systematic reviews and meta-analyses. Yasar et al.<sup>[16]</sup> demonstrated NLP's potential in detecting MAFLD through the analysis of longitudinal prescription and medical claims data. This approach uncovers patterns and risk factors that conventional methods might miss.

In clinical research, such algorithms expedite literature reviews and data extraction, crucial in the face of exponentially growing research output and knowledge dissemination.<sup>[17]</sup> While this application has not been fully utilized in hepatology yet, its potential is significant. NLP also enhances disease classification accuracy, as demonstrated by Calleja-Panero et al.<sup>[18]</sup> who utilized machine learning and NLP to analyze chronic liver disease-associated severe thrombocytopenia cases, improving classification accuracy and revealing novel clinical presentations.

Advanced machine learning techniques are driving a paradigm shift in hepatology through the integration of multi-omics data. This approach combines genomics, proteomics, metabolomics, and other -omics data to provide a comprehensive molecular understanding of liver diseases. In MAFLD, integrative multi-omics unravels the complex interplay between genetic predisposition, environmental factors, and metabolic dysregulation. Liu et al.<sup>[19]</sup> developed an artificial neural network model incorporating dietary retinol intake data to predict MAFLD risk, demonstrating the power of integrating diverse data types. Simsek et al.<sup>[10,13]</sup> used multi-omic data to stratify the risk of variceal bleeding and survival in HCC.

Machine learning algorithms excel at identifying complex patterns across multi-omics datasets. In HCC, integrative analyses of genomic, transcriptomic, and proteomic data reveal novel biomarkers and potential therapeutic targets. Deep learning models trained on multi-omics data show promise in predicting HCC recurrence and patient survival with greater accuracy than traditional clinical factors.<sup>[20]</sup>

The application of machine learning to gut microbiome data represents another frontier. Liu et al.<sup>[7]</sup>'s systematic review and meta-analysis demonstrated the effectiveness of gut microbiome-based machine learning models in predicting liver cirrhosis or fibrosis, highlighting the potential of integrating microbiome data with other -omics and clinical data.

AI integration into digital pathology is transforming liver histology interpretation, offering enhanced accuracy, reproducibility, and efficiency. Deep learning algorithms demonstrate remarkable proficiency in the automated analysis of liver biopsy images, accurately quantifying key histological features such as fibrosis, steatosis, and inflammation. In MAFLD, AI-powered digital pathology tools enhance disease classification and severity assessment accuracy. Feng et al.<sup>[1]</sup> showed that a machine learning algorithm outperformed traditional fibrosis markers in predicting significant fibrosis in biopsy-confirmed MAFLD, potentially identifying subtle histological patterns that elude human observation. For HCC, AI algorithms assist in tumor grading and classification based on histological features.<sup>[21]</sup> In liver transplantation, AI-assisted digital pathology shows promise in assessing donor livers and predicting post-transplant outcomes.<sup>[22]</sup> As AI advances in digital pathology, challenges such as the need for large, diverse, well-annotated datasets, standardization of image acquisition and processing protocols, and integration of AI tools into existing clinical workflows must be addressed.

### The Horizon: Future Directions in Hepatology AI

The future directions of AI in hepatology promise to expand its current utility across a spectrum of applications, revolutionizing liver health management. At the forefront of this transformation is the development of integrative AI systems capable of synthesizing multi-omics data with clinical parameters and environmental factors. These advanced systems will create comprehensive liver health profiles, unraveling complex interactions between genetic predispositions, environmental exposures, and the gut microbiome.

As AI-powered precision hepatology evolves, it will enable refined patient stratification based on molecular profiles, disease trajectories, and treatment responses. In HCC, AI algorithms may guide treatment selection by analyzing individual tumor genomics and immune profiles. For chronic liver diseases, AI systems may predict disease courses and treatment responses with unprecedented accuracy, optimizing management strategies. In liver transplantation, AI can enhance organ allocation and post-transplant care, potentially improving long-term graft survival rates.

The application of AI in drug discovery for liver diseases holds immense promise. By analyzing vast chemical libraries, genomic databases, and protein interaction networks, AI can accelerate the identification of novel therapeutic targets. AI-powered virtual screening may rapidly identify promising compounds, considering drug-target interactions, off-target effects, and pharmacokinetics. In clinical practice, advanced AI systems can serve as intelligent assistants, enhancing diagnostic accuracy and treatment decision-making. These systems will access vast knowledge bases, identifying subtle patterns in clinical presentations, laboratory results, and imaging studies. By generating differential diagnoses with associated probabilities and providing personalized treatment recommendations, AI may continuously update its insights based on new evidence, supporting clinicians in delivering optimal care.

The future of liver health monitoring also lies in AI-enabled wearable devices and implantable sensors, allowing for continuous, real-time assessment of liver function parameters. For patients with chronic liver diseases, AI will predict impending complications, enabling proactive management. The emergence of systems hepatology, powered by AI, will integrate knowledge from various disciplines to create comprehensive models of liver health and disease. These systems hepatology will contribute to the development of *in silico* liver models, simulating complex physiological processes and predicting intervention outcomes with unprecedented accuracy.

### Overcoming Hurdles: Challenges in AI Implementation

However, the successful implementation of AI in hepatology faces significant challenges. The development of a robust, globally interconnected data ecosystem is hindered by heterogeneous data collection methods, storage formats, and regulatory frameworks across diverse healthcare systems. While standardization initiatives such as FHIR offer promising interoperability frameworks, their adoption in hepatology necessitates concerted efforts from international bodies and stakeholders.<sup>[23]</sup> Central to this endeavor is the creation of inclusive, multi-ethnic databases, crucial for developing generalizable AI models.

As AI models in hepatology grow increasingly sophisticated, ensuring their interpretability becomes paramount. Techniques such as SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations) are being investigated to elucidate AI decision-making processes in liver disease prediction and treatment recommendations.<sup>[24]</sup> These approaches aim to demystify the “black box” nature of complex AI algorithms, providing clinicians with insights into how predictions and recommendations are generated. Complementing these efforts, hybrid models that combine the predictive power of deep learning with the interpretability of traditional statistical methods are being developed. These models strive to provide clinicians with both accurate predictions and understandable rationales, facilitating trust and informed decision-making. The ethical implementation of AI in hepatology encompasses a broad spectrum of considerations, including fairness, accountability, and societal impact. Bias mitigation stands at the forefront of these concerns, requiring rigorous evaluation of AI models for potential biases related to race, ethnicity, gender, or socio-

economic status. This ongoing process demands the use of diverse training datasets and continuous performance monitoring across various patient subgroups to ensure equitable outcomes.

As AI technologies advance, there is a pressing need to address the potential exacerbation of healthcare disparities. Striking a balance between improved care in resource-limited settings and equitable access to advanced technologies remains a significant challenge. To navigate this complex landscape, robust accountability frameworks are necessary to delineate responsibilities among developers, healthcare providers, and regulatory bodies. The ethical implications of AI-driven decisions in critical areas such as liver transplant allocation require careful consideration. These systems must balance the potential for improved outcomes with principles of fairness and equity in organ distribution, a task that demands ongoing ethical scrutiny and refinement.

### Bridging Gaps: Towards a Future of AI-Enhanced Hepatology

Addressing these multifaceted challenges requires a collaborative, multidisciplinary approach involving hepatologists, data scientists, ethicists, and policymakers. Proactive efforts by hepatologists are essential to ensure that AI advancements translate into equitable improvements in global liver health outcomes, bridging gaps in care while upholding ethical standards and patient rights. The AI-empowered future of hepatology holds immense promise for improving liver health outcomes globally. It envisions precision hepatology with personalized risk assessment and treatment selection across the spectrum of liver diseases. AI-powered tools will democratize expertise, extending expert-level care to underserved regions. Research and drug discovery will accelerate through AI-driven hypothesis generation and validation, expediting scientific breakthroughs. Continuous liver health monitoring will enable real-time assessment and proactive interventions, while global liver health surveillance will facilitate early detection of emerging trends and outbreaks. The integration of AI in hepatology represents a paradigm shift in liver disease management and research. The future of hepatology lies in the synergistic collaboration between human expertise and artificial intelligence, ushering in an era of precision hepatology that promises to elevate the standard of liver care globally.

**Use of AI for Writing Assistance:** Not declared.

### References

- Feng G, Zheng KI, Li YY, Rios RS, Zhu PW, Pan XY, et al. Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD. *J Hepatobiliary Pancreat Sci* 2021;28(7):593-603.
- Lee IC, Tsai YP, Lin YC, Chen TC, Yen CH, Chiu NC, et al. A hierarchical fusion strategy of deep learning networks for detection and segmentation of hepatocellular carcinoma from computed tomography images. *Cancer Imaging* 2024;24(1):43.
- Zhang Y, Lv X, Qiu J, Zhang B, Zhang L, Fang J, et al. Deep Learning With 3D Convolutional Neural Network for Noninvasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma. *J Magn Reson Imaging* 2021;54(1):134-143.
- Jin J, Jiang Y, Zhao YL, Huang PT. Radiomics-based machine learning to predict the recurrence of hepatocellular carcinoma: A systematic review and meta-analysis. *Acad Radiol* 2024;31(2):467-479.
- Tiyarattanachai T, Apiparakoon T, Chaichuen O, Sukcharoen S, Yimsawad S, Jangsirikul S, et al. Artificial intelligence assists operators in real-time detection of focal liver lesions during ultrasound: A randomized controlled study. *Eur J Radiol* 2023;165:110932.
- Yang Q, Wei J, Hao X, Kong D, Yu X, Jiang T, et al. Improving B-mode ultrasound diagnostic performance for focal liver lesions using deep learning: A multicentre study. *EBioMedicine*. 2020;56:102777.
- Liu X, Liu D, Tan C, Feng W. Gut microbiome-based machine learning for diagnostic prediction of liver fibrosis and cirrhosis: a systematic review and meta-analysis. *BMC Med Inform Decis Mak* 2023;23(1):294.
- Nitski O, Azhie A, Qazi-Arisar FA, Wang X, Ma S, Lilly L, et al. Long-term mortality risk stratification of liver transplant recipients: real-time application of deep learning algorithms on longitudinal data. *Lancet Digit Health* 2021;3(5):e295-e305.
- Anushiravani A, Alswat K, Dalekos GN, Zachou K, Örmeci N, Al-Busafi S, et al. Multicenter validation of FIB-6 as a novel machine learning non-invasive score to rule out liver cirrhosis in biopsy-proven MAFLD. *Eur J Gastroenterol Hepatol* 2023;35(11):1284-1288.
- Simsek C, Sahin H, Emir Tekin I, Koray Sahin T, Yasemin Balaban H, Sivri B. Artificial intelligence to predict overall survivals of patients with cirrhosis and outcomes of variceal bleeding. *Hepatol Forum* 2021;2(2):55-59.
- Zhang Z, Wang J, Han W, Zhao L. Using machine learning methods to predict 28-day mortality in patients with hepatic encephalopathy. *BMC Gastroenterol* 2023;23(1):111.
- Li X, Bao H, Shi Y, Zhu W, Peng Z, Yan L, et al. Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma. *Medicine (Baltimore)* 2023;102(45):e35892.
- Simsek C, Can Guven D, Koray Sahin T, Emir Tekin I, Sahan O, Yasemin Balaban H, Yalcin S. Artificial intelligence method to predict overall survival of hepatocellular carcinoma. *Hepatol Forum* 2021;2(2):64-68.
- Ren F, Ding X, Zheng M, Korzinkin M, Cai X, Zhu W, et al. AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor. *Chem Sci* 2023;14(6):1443-1452.
- Hoehme S, Hammad S, Boettger J, Begher-Tibbe B, Bucur P, Vibert E, et al. Digital twin demonstrates significance of biomechanical growth control in liver regeneration after partial hepatectomy. *iScience* 2022;26(1):105714.
- Yasar O, Long P, Harder B, Marshall H, Bhasin S, Lee S, et al. Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH). *BMJ Health Care Inform* 2022;29(1):e100510.
- van Dijk SHB, Brusse-Keizer MGJ, Bucsán CC, van der Palen J, Doggen CJM, Lenferink A. Artificial intelligence in systematic reviews: promising when appropriately used. *BMJ Open* 2023;13(7):e072254.
- Calleja-Panero JL, Esteban Mur R, Jarque I, Romero-Gómez M, Group SR, García Labrador L, González Calvo J. Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing. *Gastroenterol Hepatol* 2024;47(3):236-245. [English, Spanish]
- Liu C, Sun X, Peng J, Yu H, Lu J, Feng Y. Association between dietary vitamin A intake from different sources and non-alcoholic fatty liver disease among adults. *Sci Rep* 2024;14(1):1851.
- Lai Q, Spoletini G, Mennini G, Laureiro ZL, Tsilimigras DI, Pawlik TM, et al. Prognostic role of artificial intelligence among patients with hepatocellular cancer: A systematic review. *World J Gastroenterol* 2020;26(42):6679-6688.
- Ren S, Qi Q, Liu S, Duan S, Mao B, Chang Z, et al. Preoperative prediction of pathological grading of hepatocellular carcinoma using machine learning-based ultrasonics: A multicenter study. *Eur J Radiol* 2021;143:109891.
- Narayan RR, Abadilla N, Yang L, Chen SB, Klinkachorn M, Eddington HS, et al. Artificial intelligence for prediction of donor liver allograft steatosis and early post-transplantation graft failure. *HPB (Oxford)* 2022;24(5):764-771.
- Ayaz M, Pasha MF, Alzahrani MY, Budiarto R, Stiawan D. The fast health interoperability resources (FHIR) standard: Systematic literature review of implementations, applications, challenges and opportunities. *JMIR Med Inform* 2021;9(7):e21929.
- Cao HQ, Nguyen HTT, Nguyen KVT, Pham NDK. Evaluation of explainable artificial intelligence: SHAP, LIME, and CAM. *Proceedings of the FPT AI Conference*. 2021-08-20, 2021.